Get the Stockscreener App
34.07
7.71%
2.44
Viking Therapeutics Inc stock is traded at $34.07, with a volume of 15.58M.
It is up +7.71% in the last 24 hours and up +3.65% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$31.63
Open:
$31.83
24h Volume:
15.58M
Relative Volume:
3.84
Market Cap:
$3.80B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-36.63
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
+11.78%
1M Performance:
+3.65%
6M Performance:
-47.39%
1Y Performance:
-3.16%
1-Day Range:
$31.50
$36.39
1-Week Range:
$28.90
$36.39
52-Week Range:
$28.64
$99.41
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
34.07 | 3.80B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Why Viking Therapeutics Inc. (VKTX) Surged On Friday? - Insider Monkey
Viking Therapeutics jumps amid renewed takeover speculation - MSN
Viking Therapeutics jumps amid renewed takeover speculation (VKTX:NASDAQ) - Seeking Alpha
Why Viking Therapeutics Surged Despite Grim Earnings - Jomfruland.net
Kwani Viking Therapeutics Akwai Tashi Duk Da Mummunan Ribar - Jomfruland.net
(VKTX) Investment Analysis - Stock Traders Daily
Why Viking Therapeutics, Inc. (VKTX) Went Up On Wednesday? - Yahoo Finance
10 Stocks Stand Strong Amid Cautious Market Environment - Insider Monkey
Why Viking Therapeutics Stock Plummeted by 24% in December - MSN
VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10% - MSN
Viking Therapeutics, Inc. (NASDAQ:VKTX) Sees Large Increase in Short Interest - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Shares Down 1.2%Here's What Happened - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Coverage Initiated at Scotiabank - MarketBeat
Scotiabank Initiates Coverage of Viking Therapeutics (VKTX) with Sector Outperform Recommendation - MSN
Viking Therapeutics (NASDAQ:VKTX) Shares Up 3.3%Here's Why - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Shares Up 3.4%Should You Buy? - MarketBeat
Viking Therapeutics Stock Climbs On Q2 EPS Beat - MSN
Mirae Asset Global Investments Co. Ltd. Purchases New Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Stock Price Up 3.4%Here's Why - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Hits New 1-Year LowWhat's Next? - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Shares Down 1.3%Here's What Happened - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Trading Down 1.2%Here's Why - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 1.7%Here's What Happened - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 4.9% on Analyst Downgrade - MarketBeat
Scotiabank Initiates Coverage of Viking Therapeutics (LSE:0VQA) with Sector Outperform Recommendation - Nasdaq
Viking Therapeutics (NASDAQ:VKTX) Trading Down 4.9% After Analyst Downgrade - MarketBeat
Q1 Earnings Forecast for VKTX Issued By HC Wainwright - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Trading Down 1.3%Here's What Happened - MarketBeat
3 Weight-Loss Drug Stocks to Watch - Schaeffers Research
Viking Therapeutics (NASDAQ:VKTX) Earns Sector Outperform Rating from Analysts at Scotiabank - MarketBeat
Scotiabank initiated coverage on Viking Therapeutics with a new price target - Quantisnow
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Scotiabank Initiates Viking Therapeutics at Sector Outperform -February 13, 2025 at 07:39 am EST - Marketscreener.com
William Blair Expects Lower Earnings for Viking Therapeutics - MarketBeat
Why Viking Therapeutics Inc. (VKTX) Went Down on Monday - MSN
These 10 Companies Led Monday’s Downturn - Insider Monkey
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today - Benzinga
Viking Therapeutics (NASDAQ:VKTX) Coverage Initiated by Analysts at Citigroup - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Given New $70.00 Price Target at Maxim Group - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Earns "Buy" Rating from B. Riley - MarketBeat
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today - Nasdaq
FY2027 Earnings Estimate for VKTX Issued By William Blair - MarketBeat
2 Stocks to Buy With Less Than $40 - Yahoo Finance
Viking Therapeutics Stock Price Forecast for 2025 - Markets.com
Viking Therapeutics started at neutral by Citi - MSN
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):